First IndiTreat® order received from Labormed, Slovenia

December 22 | 2021

2cureX, Leader in Oncology Drug Sensitivity Testing, announced today that the company has received its first order for an IndiTreat® product. This milestone has been long expected as it signals the start of a new stage for IndiTreat®. The order, small but of strategic importance, was placed by Labormed, 2cureX’s distributor in Slovenia, for IndiTreat® Sample Collection Sets.

The IndiTreat® Sample Collection Set contains all the elements used by IndiTreat® customers to store the patient tissue sample and preserve it through the transportation from the hospital to 2cureX labs in Copenhagen.

Hospitals need to get these Sample Collection Sets from the distributors in each country prior to scheduling the patient´s biopsy, therefore getting this first order is an important proof point that the process to start using IndiTreat® in hospitals has finally been set in motion. Recurrent orders are expected from this and other distributors as hospitals gradually integrate IndiTreat® to the portfolio of technologies used by their Oncologists.

With this achievement, 2cureX completes all the business goals it had announced for 2021, namely:

  • Getting ISO 13485 certification
  • Successful completion of the TICC trial in metastatic colorectal cancer (supported by EU MicroCaT project – H2020 no. 777718)
  • Launching two IndiTreat® tests – IndiTreat® Start and IndiTreat® Extend
  • Having distribution agreements covering 11 countries and 20% of European population
  • Assembling a new Advisory Board specialized in GI cancers
  • Launching an early access program – IGNITE – and enrolling the first hospitals to it
  • Getting the first IndiTreat® sales

Outstanding year for 2cureX

“This has been an outstanding year for 2cureX” said Fernando Andreu, CEO of 2cureX. “We have built a very solid foundation for our future expansion, at a speed that was only possible thanks to the exceptional commitment and dedication of our team, and our business and clinical partners. We are looking very much forward to an exciting 2022”.

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The IndiTreat® portfolio includes IndiTreat® mCRC Start, a test to guide 1st line therapy selection in patients with colorectal cancer, and IndiTreat® mCRC Extend, for treatment decision-making in patients who have undergone at least two previous therapy lines. Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se

This information is information that 2cureX is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-12-22 08:45 CET.

Attachments

First IndiTreat® order received from Labormed, Slovenia

Previous Next